Rethinking the TKA Recovery Curve: New Insights from MOTIV™
June 2, 2026
Rethinking the TKA Recovery Curve: New Insights from MOTIV™
Are we settling for a plateau in TKA post-operative pain recovery?
New preliminary data from the MOTIV™ study is challenging what we expect from long-term Total Knee Arthroplasty (TKA) outcomes. By tracking patients who utilized a non-opioid pain management agent as part of their surgical protocol, we are seeing a remarkable shift in the recovery curve.
.png)
Key Takeaways from the data:
- Higher Starting Point, Steeper Drop: The targeted cohort began with significantly higher pre-operative pain levels (5.6 VAS) compared to the broader patient baseline (4.3 VAS). Despite this, they experienced a sharp, significant reduction by the two-week mark.
- Sustained Relief: In the traditional TKA recovery cohort, pain reduction plateaus at 3 months (~2.0 VAS). However, the non-opioid cohort showed a continuous, sustained decline over the same period.
- The 90-Day Difference: At 3 months, the non-opioid group achieved a remarkably low final pain score (~1.0), outperforming the general population and proving the value of integrated, non-opioid pain strategies.
These insights reinforce our commitment to non-opioid strategies that prioritize both safety and superior surgical outcomes.
Interested in the full MOTIV™ dataset? Let’s start the conversation.
Rethinking the TKA Recovery Curve: New Insights from MOTIV™
June 2, 2026
Are we settling for a plateau in TKA post-operative pain recovery?
New preliminary data from the MOTIV™ study is challenging what we expect from long-term Total Knee Arthroplasty (TKA) outcomes. By tracking patients who utilized a non-opioid pain management agent as part of their surgical protocol, we are seeing a remarkable shift in the recovery curve.
Key Takeaways from the data:
- Higher Starting Point, Steeper Drop: The targeted cohort began with significantly higher pre-operative pain levels (5.6 VAS) compared to the broader patient baseline (4.3 VAS). Despite this, they experienced a sharp, significant reduction by the two-week mark.
- Sustained Relief: In the traditional TKA recovery cohort, pain reduction plateaus at 3 months (~2.0 VAS). However, the non-opioid cohort showed a continuous, sustained decline over the same period.
- The 90-Day Difference: At 3 months, the non-opioid group achieved a remarkably low final pain score (~1.0), outperforming the general population and proving the value of integrated, non-opioid pain strategies.
These insights reinforce our commitment to non-opioid strategies that prioritize both safety and superior surgical outcomes.
Interested in the full MOTIV™ dataset? Let’s start the conversation.
